Antibody response to mRNA vaccination for COVID-19 in patients with AML receiving hypomethylating agents alone or with venetoclax

Detalles Bibliográficos
Autores principales: Candoni, Anna, Callegari, Chiara, Zannier, Maria Elena, Fanin, Renato
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8813197/
https://www.ncbi.nlm.nih.gov/pubmed/35108726
http://dx.doi.org/10.1182/bloodadvances.2021006949
_version_ 1784644795555119104
author Candoni, Anna
Callegari, Chiara
Zannier, Maria Elena
Fanin, Renato
author_facet Candoni, Anna
Callegari, Chiara
Zannier, Maria Elena
Fanin, Renato
author_sort Candoni, Anna
collection PubMed
description
format Online
Article
Text
id pubmed-8813197
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Society of Hematology
record_format MEDLINE/PubMed
spelling pubmed-88131972022-02-04 Antibody response to mRNA vaccination for COVID-19 in patients with AML receiving hypomethylating agents alone or with venetoclax Candoni, Anna Callegari, Chiara Zannier, Maria Elena Fanin, Renato Blood Adv Research Letter American Society of Hematology 2022-05-18 /pmc/articles/PMC8813197/ /pubmed/35108726 http://dx.doi.org/10.1182/bloodadvances.2021006949 Text en © 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved. https://www.ncbi.nlm.nih.gov/pmc/pmcdoc/tagging-guidelines/article/tags.html#el-licenseThis article is made available via the PMC Open Access Subset for unrestricted reuse and analyses in any form or by any means with acknowledgment of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.
spellingShingle Research Letter
Candoni, Anna
Callegari, Chiara
Zannier, Maria Elena
Fanin, Renato
Antibody response to mRNA vaccination for COVID-19 in patients with AML receiving hypomethylating agents alone or with venetoclax
title Antibody response to mRNA vaccination for COVID-19 in patients with AML receiving hypomethylating agents alone or with venetoclax
title_full Antibody response to mRNA vaccination for COVID-19 in patients with AML receiving hypomethylating agents alone or with venetoclax
title_fullStr Antibody response to mRNA vaccination for COVID-19 in patients with AML receiving hypomethylating agents alone or with venetoclax
title_full_unstemmed Antibody response to mRNA vaccination for COVID-19 in patients with AML receiving hypomethylating agents alone or with venetoclax
title_short Antibody response to mRNA vaccination for COVID-19 in patients with AML receiving hypomethylating agents alone or with venetoclax
title_sort antibody response to mrna vaccination for covid-19 in patients with aml receiving hypomethylating agents alone or with venetoclax
topic Research Letter
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8813197/
https://www.ncbi.nlm.nih.gov/pubmed/35108726
http://dx.doi.org/10.1182/bloodadvances.2021006949
work_keys_str_mv AT candonianna antibodyresponsetomrnavaccinationforcovid19inpatientswithamlreceivinghypomethylatingagentsaloneorwithvenetoclax
AT callegarichiara antibodyresponsetomrnavaccinationforcovid19inpatientswithamlreceivinghypomethylatingagentsaloneorwithvenetoclax
AT zanniermariaelena antibodyresponsetomrnavaccinationforcovid19inpatientswithamlreceivinghypomethylatingagentsaloneorwithvenetoclax
AT faninrenato antibodyresponsetomrnavaccinationforcovid19inpatientswithamlreceivinghypomethylatingagentsaloneorwithvenetoclax

Ejemplares similares